Proqr hopes to usher in a new ophthalmic therapy

Mixed mid-stage data on Proqr’s exon skipper QR-421a in the rare ophthalmic disorder Usher syndrome were released early on Wednesday morning to widespread apathy. Yesterday, however, the company’s stock shot up 61%. It is not clear why this reaction was delayed.